A preview of the April 1 FDA advisory panel convened to review MannKind's inhaled insulin device.
Synta isn't saying why Safi Bahcall resigned as CEO but the stock has severely underperformed the market for the past year.
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
An epic month of biotech stock performance ends with a significant sell off.
InterMune's Esbriet improved lung function and delayed disease progression in pivotal phase III study.
The No. 1 stock on this list has more than half its float short.
Sales of the prescription fish-oil are so low that generic drug makers may simply pass the product by.
The decision to change out the primary and secondary endpoints was made as part of discussions with the FDA, a Vertex spokesman said.
Biotech investing goes mainstream.